MLYS Mineralys Therapeutics
- 13.500
- -0.770-5.40%
Mineralys Therapeutics News
Mineralys Therapeutics: Strong Buy on Upcoming ADVANCE Trial Results and Robust Financial Health
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Anika Therapeutics (ANIK)
Mineralys Therapeutics Q1 2024 GAAP EPS $(0.70) Misses $(0.67) Estimate
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.67) by 4.48 percent. This is a 37.25 percent decrease over losses
Mineralys Therapeutics | 10-Q: Quarterly report
Mineralys Therapeutics 1Q Loss $31.5M >MLYS
Mineralys Therapeutics 1Q Loss $31.5M >MLYS
Mineralys Therapeutics Cash, Cash Equivalents and Investments Were $338.6M as of March 31 >MLYS
Mineralys Therapeutics Cash, Cash Equivalents and Investments Were $338.6M as of March 31 >MLYS
Press Release: Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update -- Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topl
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD)
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic
Mineralys Therapeutics Board Member Announces Departure
Goldman Starts Mineralys at Buy, Cites Upcoming Drug Data
QuidelOrtho Stock Falls 11% on Savanna PVP4+ Assay Update
Goldman Sachs Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30
Goldman Sachs analyst Richard Law initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $30.
Mineralys Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 126.93% Goldman Sachs → $30 Initiates Coverage On → Buy 08/08/2023 179.88% Credit Suisse $38 →
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript
Analysts Offer Insights on Healthcare Companies: Resmed (RMD), Mineralys Therapeutics, Inc. (MLYS) and Addus Homecare (ADUS)
Buy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic Developments
Earnings Call Summary | Mineralys Therapeutics(MLYS.US) Q4 2023 Earnings Conference
The following is a summary of the Mineralys Therapeutics, Inc. (MLYS) Q4 2023 Earnings Call Transcript:Financial Performance:Mineralys ended 2023 with cash, cash equivalents and investments totaling $
Mineralys Therapeutics Files Mixed-Securities Shelf Registration
Mineralys Therapeutics (MLYS) on Thursday filed a registration statement with the US Securities and Exchange Commission to sell up to $500 million of its securities from time to time. The securities m
Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...
Analysis
Price Target
No Data
